welcome
We've been working on it

Central venous drug administration will see a price reduction!

Following the price standardization and management of CT, tumor markers and other examination and testing items, another important price management achievement has brought good news to more than 3 million patients who need chemotherapy and long-term infusion – central venous administration will usher in a price reduction!

Sun Wenyan, head nurse of the Department of Clinical Nutrition at Peking Union Medical College Hospital, is performing a PICC catheter through a peripheral venous puncture for a patient. Photo by Xinhua News Agency reporter Xu Penghang

The National Health Insurance Administration issued a letter on February 21 to inform all localities of the results of the comprehensive management of central intravenous drug delivery prices, involving infusion ports (PORT), peripheral venous puncture central venous catheters (PICC) and central venous catheters (CVC), and the relevant fees will be adjusted in place in the near future.

The overall cost of PORT will be reduced from about 6,000 yuan to about 3,300 yuan; The overall cost of PICC will be reduced from about 3,000 yuan to about 1,300 yuan; The overall cost of CVC will be reduced from more than 800 yuan to about 450 yuan…… Behind the price reduction is the warmth of making the treatment of patients more convenient, and it is also the peace of mind of “reducing the burden” for patients and their families.

Central intravenous administration is a method of direct infusion of drugs through a large vein near the heart, and the catheter used is usually only about 1.5 mm in diameter, which is the “life channel” of the patient. After the catheter is implanted, it can not only stay in the body for a long time, so that the patient can avoid the pain of repeated punctures, but also allow the drug to “go directly” to the large veins near the heart, reducing blood vessel damage. However, its high cost often becomes a burden for patients, and even makes some patients “shy away”.

For the sake of the health and well-being of patients, the National Health Insurance Administration continues to carry out price governance to squeeze out the price moisture caused by excessive price increases in the circulation link. Previously, the National Health Insurance Administration has guided Henan Province to take the lead in the inter-provincial alliance procurement of related consumables, and this price management will further guide more central venous drug delivery consumables to be more reasonable.

Nurses from Peking Union Medical College Hospital perform peripheral venous catheter maintenance on patients. Photo by Xinhua News Agency reporter Xu Penghang

“Patients can use drug delivery devices that can be kept in the body for a relatively long time, which is conducive to reducing the physiological and economic burden caused by long-term treatment, and is also conducive to improving the accessibility of related products and promoting the improvement of medical service effectiveness.” Sun Wenyan, head nurse of the clinical nutrition department of Peking Union Medical College Hospital, said.

While squeezing unreasonable prices and “reducing the burden” on patients, it is very important to regulate the price of medical services.

“The cost of technical labor for central intravenous administration has been greatly different from place to place, with a few provinces having high prices and most provinces having low prices.” The relevant person in charge of the National Health Insurance Bureau said that in this regard, the comprehensive price management unified and standardized the name and price level of the relevant medical service price items, and the National Health Insurance Bureau guided a few high-priced provinces to lower prices, and other low-priced provinces to appropriately raise prices, and the specific price level can fluctuate around the benchmark price by no more than 10%.

“Central intravenous drug administration has high technical requirements for medical staff, and the unified standardization of technical labor costs is helpful to more reasonably reflect the labor value of medical staff, and it is also an affirmation of medical staff.” Sun Wenyan said.

Price governance is a “heart-warming strategy” to reduce the burden of patients, a “bridge to the heart” to communicate between doctors and patients, and an “ice-breaking move” for medical reform to enter the deep water area. It is reported that the National Health Insurance Administration will continue to carry out work related to the governance of pharmaceutical prices, so that more people’s livelihood can benefit and warm people’s hearts and illuminate the road to health.

Like(0)
未经允许不得转载:Entering China » Central venous drug administration will see a price reduction!

评论 Get first!

China Information Website

A comprehensive introduction to China's culture, economy, science and technology and education, so that the world can understand China and understand China!

联系我们联系我们

Sign In

Forgot Password

Sign Up